Invention Grant
US09023364B2 Vaccine antigen capable of inducing cross-reacting and neutralizing antibody against high-risk-type human papillomavirus
有权
能够诱导针对高风险型人乳头状瘤病毒的交叉反应和中和抗体的疫苗抗原
- Patent Title: Vaccine antigen capable of inducing cross-reacting and neutralizing antibody against high-risk-type human papillomavirus
- Patent Title (中): 能够诱导针对高风险型人乳头状瘤病毒的交叉反应和中和抗体的疫苗抗原
-
Application No.: US12452305Application Date: 2008-06-25
-
Publication No.: US09023364B2Publication Date: 2015-05-05
- Inventor: Tadahito Kanda , Kazunari Kondo
- Applicant: Tadahito Kanda , Kazunari Kondo
- Applicant Address: JP Tokyo
- Assignee: Japan Health Sciences Foundation
- Current Assignee: Japan Health Sciences Foundation
- Current Assignee Address: JP Tokyo
- Agency: Mintz Levin Cohn Ferris Glovsky and Popeo, P.C.
- Agent David G. Conlin; Christopher R. Cowles
- Priority: JP2007-167154 20070626
- International Application: PCT/JP2008/061569 WO 20080625
- International Announcement: WO2009/001867 WO 20081231
- Main IPC: A61K39/12
- IPC: A61K39/12 ; A61K39/00 ; C07K14/005 ; C12N7/00
Abstract:
Disclosed is a vaccine antigen capable of inducing a cross-reacting and neutralizing antibody directed against a high-risk-type human papillomavirus. Specifically disclosed are: a chimeric protein comprising an L2-epitope of a human papillomavirus (HPV) type-16 inserted in a loop region of a human papillomavirus type-16 L1 protein; and a capsid which is a particle formed by the chimeric protein. The loop region to which the L2-epitope is to be inserted is located between an amino acid residue at position-430 and an amino acid residue at position-433. The L2-epitope has an amino acid sequence represented by any one of the following formulae: LYKTCKQAGTCPPDIIPKVEG (SEQ ID NO: 2) (18-38 L2-epitope); GGLGIGTGSGTGGRTGYIPL (SEQ ID NO: 3) (56-75 L2-epitope); and DPVGPLDPSIVSLVEESSFI (SEQ ID NO: 4) (96-115 L2-epitope).
Public/Granted literature
Information query
